Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHO-H01 in Refractory or Relapsed Follicular Lymphoma
NCT03221348Phase 1Unknown
- Sponsor
- CHO Pharma
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Naked Antibodies
01
Overview
Phase 1, open-label, single-arm trial of cho-h01 in follicular lymphoma (FL), sponsored by CHO Pharma. Primary endpoints: Adverse drug reactions at 28 days and Pharmacodynamic assessment of Immune cell activation at 64 days. Status: unknown.
02
Drugs
cho-h01
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03221348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221348.